Further, it was demonstrated that the TKI Cabozantinib improves renal cell carcinoma-specific cytotoxicity by enhancing the expression of EGFR and reducing PD-L1 expression in renal cell carcinoma, working in a synergistic way with CAR-NK92 cells and improving their cytotoxicity both in vitro and in vivo [164]. This evidence concerns the gene EGFR and renal cell carcinoma.